- Lead late-stage drug substance process design, optimization, and scale-up across global CDMOs.
- Embed Quality by Design and DoE to define CPPs/CQAs and support regulatory submissions.
- Drive tech transfer, PPQ campaigns, and cGMP compliance for commercial readiness.
Pulmovant is a Roivant-backed clinical-stage biotech developing inhaled therapies for pulmonary diseases. Its lead candidate, mosliciguat, is in Phase 3 for PH-ILD, and the company operates with a collaborative, fast-paced Roivant culture.